Medicinal Genomics announced that Rose City Labs has selected Medicinal Genomics' PathoSEEK qPCR platform for microbial testing in its Portland, OR, facility, the first in that state. "Rose City is capitalizing on its position as a industry leader by also educating cultivators on field sampling and breeding, and providing cannabis genetics services to maximize yield and consistency," the team with the company explains. "Beyond cannabis, Rose City also offers testing for asbestos, radon, and once their applied-for medical license is approved, complex blood and urinalysis and of course, COVID-19."
"It's important that the lab is versatile," Dan said. "Yes, we have the cannabis businesses. But we also test for asbestos and eventually we'll do medical testing as well. But as we see it, all our clients are after the same thing; Results they can rely on to help grow their businesses. That's why we chose MGC. They're the best there is."
Full legalization passed in Oregon in 2016, right behind Colorado, but cannabis testing technology that is deployed there is primarily limited to plating, a 100-year old standard passed down from the food industry, and which lags behind advances the rest of the industry is making. This is particularly problematic for cannabis labs because plating only identifies pathogens that live on the plant and do not do a good job of identifying pathogens that are endophytic, or living in the plant. Some of cannabis' most dangerous pathogens, like four lethal species of Aspergillis, are endophytes.
"We're thrilled Dan and his team selected us to help them drive change in Oregon," said Brendan McKernan, Medicinal Genomics CEO. "Like them, we believe in the power of cannabis to support health and wellness and we look forward to many years of collaboration on that front. Taking the lead is a position we're also familiar with. We're honored to be a part of their efforts to set new standards for their state and the rest of the industry."